BASEL (dpa-AFX) - Novartis AG (NVS) reported Friday positive results from
the pivotal Phase III ASC4FIRST trial, which met both primary endpoints with
clinically meaningful and statistically significant results.

Scemblix (asciminib) demonstrated superior MMR rates at week 48 vs.
investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib)
(67.7% vs. 49.0%) and imatinib alone

Scemblix also demonstrated a favorable safety and tolerability profile vs.
imatinib and 2G TKIs, with fewer grade ?3 AEs, dose adjustments, and half the
rate of AEs leading to treatment discontinuation

This is compared to imatinib alone in patients with newly diagnosed Philadelphia
chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).

TKIs have transformed CML treatment, but unmet need remains. Many newly
diagnosed patients do not meet molecular response goals, and many discontinue or
change treatment due to intolerance2-17

Scemblix was granted US FDA Breakthrough Therapy Designation.



Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX